Singapore approves AI tool that predicts patient deterioration using vital signs.

Imec mass-produces ultra-small, uniform nanopores using EUV lithography, advancing biosensors for genomics and medicine.

PureTech Health's drug deupirfenidone advances to pivotal trial, boosting shares 4.9%.

CASI Pharma's CID-103 boosted platelets in 73% of adults with hard-to-treat low platelet counts, with a safe profile, in early trial results.

Elacestrant combo therapy shows promise for ER-positive, HER2-negative breast cancer in new trial data.

On Dec. 2, 2025, Onco-Innovations and Colorectal Cancer Canada hosted a virtual roundtable with 20 leaders to advance global precision oncology through data-driven innovation.

A new FDA-approved hepatitis C test, developed by Northwestern University, enables same-day diagnosis and treatment with 100% accuracy.

Argus downgraded Novo Nordisk to Hold due to high valuation, competition, and growth concerns, despite strong long-term fundamentals.

Higher heart fat levels after a heart attack correlate with greater heart damage, according to a 2025 study.

Lir Life Sciences finishes animal study testing needle-free patches for obesity drugs, aiming to improve treatment access and adherence.